Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

RLS GLOBAL AB (publ) YEAR-END REPORT, Q4, 2021

OCTOBER 1[st ]– DECEMBER 31[st] (previous year in brackets) · Net sales amounted to TSEK 219 (TSEK 139) · Earnings before interest and taxes (EBIT) amounted to TSEK -7 478 (TSEK -7 655) · Earning per share before dilution at SEK -0,11 (SEK -0,12) · Cash flow from operating activities amounted to TSEK -4 887 (TSEK -7 000) · Liquid assets at the end of the period TSEK 11 469 (TSEK 18 997) · Equity ratio was 75 % (87 %).  JANUARY 1[st ]– DECEMBER 31[st] (previous year in brackets) · Net sales amounted to TSEK 653 (TSEK 2 043)                      · Earnings

Wulff Group Plc: Manager Transaction - Elina Pienimäki

MANAGERS’ TRANSACTIONS  FEBRUARY 25, 2022 AT 10.00 A.M.  Wulff Group Plc has disposed on 23 February 2022 it’s own shares as a part of Wulff Group Plc’s short-term incentive scheme according to the decision by the Board of Directors on 21 February 2022. Detailed information about the transaction is given in the table below.   Name: Elina PienimäkiPosition: CEOIssuer: Wulff Group PlcLEI: 74370016PW2V4W02LX91Notification type: Initial notificationReference number: 10420/5/4

Notice of Indutrade AB's 2022 Annual General Meeting

The Annual General Meeting of Indutrade Aktiebolag (publ) (reg. no. 556017-9367) will be held on Tuesday, 5 April 2022.This is a non-official translation of the Swedish original wording. In case of differences between the English translation and the Swedish original, the Swedish text shall prevail.Due to the coronavirus, Indutrade has decided that the Annual General Meeting shall be conducted without the physical presence of shareholders, representatives or third parties, and that shareholders shall have the opportunity to exercise their voting rights only by postal voting. Information on

Axfood publishes Annual and Sustainability Report 2021

Axfood’s Annual and Sustainability Report 2021 has been published and is now available on the Group’s website.– As we now put 2021 behind, I can confidently say that the past year has probably been the most intense and exceptional year in Axfood’s history. Despite operating in the midst of a pandemic, with restrictions and a number of upheavals, we strengthened our market positions and implemented major structural changes that are increasing our competitiveness. The developments we are now implementing are creating the prerequisites for long-term, profitable and sustainable growth, says

Year-end report 2021

Gradientech AB (publ) year-end report for 2021 is now available on the company's website www.gradientech.se.Fourth quarter October-December 2021 · Net sales amounted to 0 KSEK (24 KSEK). · Net profit amounted to -17,860 KSEK (-10,036 KSEK). · Earnings per share were SEK -1.46 (SEK -1.03). · Cash flow from operating activities amounted to -17,288 KSEK (-9,876 KSEK). · Cash and cash equivalents on the balance sheet date amounted to 14,724 KSEK (71,154 KSEK). · Equity as of December 31 amounted to 93,770 KSEK (75,760 KSEK). · The annual external audit (bsi) of the

Resqunit AB - 2021 Fourth Quarter Report

Resqunit AB today announced fourth quarter 2021 results. "Project developments over the past months have further strengthened our belief in the tremendous growth potential. 2021 has largely been focused around R&D activities and prototype field testing with several partners around the world. During the fourth quarter, our main product line-up has been established and are being prepared for mass-production. We're confident that this will result in strong growth in the time to come," says Helge Trettø Olsen, CEO of Resqunit AB.Net sales amounted to SEK 67 thousand for the year 2021, a

Eevia Health Plc Interim Report Quarter 4 – 2021

THE BOARD AND CEO OF EEVIA HEALTH PLC PRESENT THE YEAR-END REPORT FOR JANUARY 1 – DECEMBER 31, 2021, INCLUDING THE INTERIM REPORT FOR THE FOURTH QUARTER OF 2021.Significant events during the fourth quarter and full-year 2021: · Net sales for the year grew by over 130% compared to 2020, amounting to the total revenue of KEUR 6,671. · During Q4, 2021 Net sales amounted to KEUR 658 compared to KEUR 1,534 in 2020. The underlying Net Sales in Q4, 2021 was KEUR 801. The underlying revenue was higher than the reported revenue. Eevia credited one sold batch in Q4-21 that needed reprocessing.

Heliospectra (publ) Publish Year-End Report 2021

(Gothenburg, Sweden February 25, 2022, at 08:45 CET)– Heliospectra AB (publ (Nasdaq First North Growth Market: HELIO), a leader in intelligent lighting technology for greenhouse and controlled plant growth environments, presents its’ Year-End Report for 2021.Full report is enclosed to this press release and is also uploaded at https://www.heliospectra.com/investor-relations/investor-relations. SUMMARY OF REPORT Financial Performance for the period October - December and January – December Order intake during the period October - December amounted to SEK 4,248 (9,440) thousand. For

STENOCARE enters the UK market with three medical cannabis oil products

STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER:  STENO STENOCARE A/S (“STENOCARE”) to make medical cannabis oil products available for UK patients. With this STENOCARE is taking a major step towards its goal of becoming a European market leader. STENOCARE has been working extensively on the regulatory approval in the UK and considers the current timing to be good given that industry analysts have projected that the UK will become one of Europe’s largest markets in five years. Delivery of first products to the UK market is expected in 60-90 days.This information is

BioStock: Cereno Scientific strengthens R&D organisation

Swedish biotech Cereno Scientific has recruited Fredrik Frick as Head of Clinical Operations. The addition to the company’s executive management team further strengthens its R&D organisation, as Cereno eyes a scenario with up to three clinical programmes in its pipeline by 2023.Read the article at biostock.se: https://www.biostock.se/en/2022/02/cereno-scientific-strengthens-rd-organisation/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Hamlet Pharma AB Interim Report Q2; October – December 2021

Opening remarks The second quarter of the fiscal year 2021/2022 has been very productive ending on a high with the completion of the clinical part of the dose-escalation study in December. The positive outcome was communicated in January 2022, showing stronger effects on the tumors with higher doses of Alpha1H. No drug related side effects were detected, further strengthening the profile of Alpha1H as a drug candidate with a high level of tumor specificity. These findings inspire us to proceed with the drug development towards Phase III trials. The dialogue with our US partners Target

Pharmacolog's Year-end Bulletin 2020

Press release: Uppsala, February 25, 2022. Pharmacolog i Uppsala AB’s (publ) Year-end Bulletin 2021 is now available on the company’s webbsite www.pharmacolog.com (Swedish only)Fjärde kvartalet 1 oktober – 31 december 2021 · Koncernens nettoomsättning för perioden uppgick till 3 838 (866) KSEK. · Rörelseresultatet för koncernen för perioden uppgick till -2 976 (-4 449) KSEK. · Nettoresultat per aktie före och efter utspädning var för perioden -0,20 (-0,35) SEK. Perioden 1 januari – 31 december 2021 · Koncernens nettoomsättning för perioden uppgick till 8 816 (1 901) KSEK.

YEAR END REPORT Period from January 2021 to December 2021

Peptonic Medical Israel Ltd and CommonSense Marketing Inc is consolidated in the group from 2021-10-20 Peptonic Medical AB (publ) org nr 556776-3064 (www.aktietorget.se ticker: PMED) Group, Peptonic Medical Israel Ltd and CommonSense Marketing Inc are included from 2021-10-20 2021 FOURTH QUARTER (Oct-Dec) · Net sales of products KSEK 5,642 (7,258) · Gross profit KSEK 3,388 (3,866), Gross margin 60% (53%) · Operating loss KSEK -43,974 (-10,702)  · Loss per share SEK -0.23 (-0.07) FULL YEAR 2021 (Jan-Dec) · Net sales of products KSEK 31,643 (21,283) · Gross

Quartiers Properties’ Year-End Report – January to December 2021

Today Quartiers Properties AB (publ) published the company’s year-end report for the period January to December 2021Summary of the period THE PERIOD OCTOBER – DECEMBER 2021 · Net sales for the fourth quarter totalled SEK 49,784 (10,131) thousand. · The company's cash flow from operating activities, including the sale of housing, amounted to SEK 24,549 (-17,051) thousand. · Revenue from the operator business, including Boho Club and the company's apartment rental business, amounted toSEK 15,883 (6,653) thousand, corresponding to an increase of SEK 9,230 thousand, or 139%

Everon is the first fintech company to be crowned Switzerland’s best asset manager of the last 12 months

Once again, Everon performed outstandingly in the asset manager rankings compiled by BILANZ. Alongside the title of ‘Asset Manager of the Year’, the Zurich-based fintech company took first place in two further contests and second place in another. This demonstrates that Everon is not just succeeding in combining digital private banking with easy usability and affordable terms: the company is generating hefty returns, too.(Zurich) Back in 2021, Everon took second place in the ranking of asset managers compiled every year by financial services provider firstfive 

Interim report Kährs BondCo (Publ) January 1 – December 31, 2021

HighlightsJanuary – December 2021 · On December 7, 2021, Kährs BondCo issued a sustainable linked bond of an amount of SEK 1,450 million. Amount held on escrow awaiting share purchase transactions within owner companies to make Kährs BondCo parent company of the Kährs group. Transactions planned for January 2022 · Net sales amounted to 0  · EBIT for the period amounted to SEK -0.2 million and is related to administrative expenses of the company  · Income after financial items amounted to SEK -8.4 million · Net income after taxes amounted to SEK -12.2 million · Earnings

Invitation to a Press Conference: Kamux Corporation’s Financial Statements Bulletin for 2021

Kamux Corporation     Investor News     February 25, 2022 at 9:00 (EET) Invitation to a Press Conference: Kamux Corporation’s Financial Statements Bulletin for 2021 Kamux Corporation will publish its Financial Statements Bulletin for 2021 on March 4, 2022 at approximately 9:00 a.m. Kamux will hold a Financial Statements Bulletin press conference and webcast for the media and analysts on Friday March 4, 2021 at Hotel Kämp, Symposion meeting room (address Pohjoisesplanadi 29, Helsinki) at 11:00 a.m (EET) in Finnish and then in English at approximately 12.00 a.m noon (EET). The event

Changes in Elkem's corporate management

Frederic Jacquin has been appointed as Elkem’s SVP Strategy & Business Development and Asbjørn Søvik has been appointed as Elkem's SVP Green Ventures & Digital. Mr. Jacquin will continue to head up the company's Silicones division until the replacement process has been concluded, expected by end of June 2022.Frederic Jacquin will start in his role as Senior Vice President for Strategy & Business Development from 1 March 2022. In this role, he will be responsible for corporate strategy and business development, including mergers and acquisitions (M&A) and new growth projects supporting all

Financial Report 4th quarter for DOF ASA

The Group's revenue for 4th quarter (management reporting) totals NOK 1,975 million (NOK 1,680 million) and EBITDA totals NOK 753 million (NOK 606 million). The operating profit (EBIT) is NOK 264 million (NOK -335 million), of which depreciation and impairment totals NOK 489 million (NOK 941 million). Net result is NOK -281 million (NOK 238 million). The Group’s revenue in 2021 (management reporting) totals NOK 7,544 million (NOK 7,582 million) and EBITDA totals NOK 2,790 million (NOK 2,990 million). The EBITDA includes NOK 109 million (NOK 19 million) in gain from sale of assets. The

Azelio: Year-end report 2021

Significant events Q4: Oct – Dec 2021 · The leading certification body, DNV, issued a validation report showing that the TES.POD[®] energy storage system performs in all aspects in accordance with the technical performance specification. As part of the validation, DNV performed a due diligence of Azelio’s technology, production, R&D and test facilities, as well as partaking of operational data relating to production and storage capacity, system efficiency and response times. · An order was received for 1.3 MWh of renewable electricity supply, corresponding to eight TES.POD[®]

Invitation to the presentation of Esmaeilzadeh Holding AB’s year-end report 2021

Esmaeilzadeh Holding AB (publ) will publish its year-end report 2021 on Monday, 28 February 2022, at 08:00 am CET. The company’s CEO, Saeid Esmaeilzadeh, will present the report through a video conference meeting on Tuesday, 1 March 2022, at 09:30 am CET. After the presentation, participants will have the opportunity to ask questions.   To participate, please use the link below.   Time for publication of the year-end reportMonday, 28 February 2022, at 08:00 am CET   Time for video conference callTuesday, 1 March 2022, at 09:30 am CET   Link to the video

Viaplay to include STARZPLAY in the Netherlands

· All new STARZPLAY Originals available in the Netherlands through Viaplay as part of a regular subscription · Agreement includes STARZPLAY’s line-up of films and series from Lionsgate and other major Hollywood studios · Viaplay to launch in the Netherlands on 1 March Viaplay and STARZ, a Lionsgate company, have agreed a long-term partnership that makes Viaplay a new home to STARZ’s international premium streaming service STARZPLAY in the Netherlands. All new STARZPLAY Originals will be available through Viaplay as part of a regular subscription, along with STARZPLAY’s line-up of

There are no items matching the current filter
There are no more items matching the current filter
Back to top